Gilead Enters Agreement to Acquire Nimbus Apollo for $1.2B

Gilead Sciences has entered into an agreement to acquire Nimbus Therapeutics subsidiary Nimbus Apollo and its acetyl-CoA carboxylase inhibitor program.

Under the agreement, Gilead will pay Nimbus $400 million upfront and up to $800 million in additional milestones.

Gilead will oversee development and commercialization of Nimbus’ ACC inhibitors, including NDI-010976, and other ACC inhibitors that treat nonalcoholic steatohepatitis, hepatocellular carcinoma and other conditions.  

FDA granted NDI-010976 fast track status in February.